CA2286692A1 - Molecules presentant une pluralite de groupes fonctionnels actifs - Google Patents
Molecules presentant une pluralite de groupes fonctionnels actifs Download PDFInfo
- Publication number
- CA2286692A1 CA2286692A1 CA002286692A CA2286692A CA2286692A1 CA 2286692 A1 CA2286692 A1 CA 2286692A1 CA 002286692 A CA002286692 A CA 002286692A CA 2286692 A CA2286692 A CA 2286692A CA 2286692 A1 CA2286692 A1 CA 2286692A1
- Authority
- CA
- Canada
- Prior art keywords
- groups
- polyvalent
- group
- polyvalent presenter
- presenter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/00756—Compositions, e.g. coatings, crystals, formulations
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des compositions polyvalentes permettant de présenter de façon polyvalente un agent thérapeutique. Ces compositions pharmaceutiques contiennent un agent de présentation polyvalent. Selon une réalisation, l'agent de présentation est formulé comme (Y)-(X-A)¿n?, Y étant un squelette, X une liaison directe ou un lien, A un groupe fonctionnel à fonction de présentation, et n un entier supérieur à 10 choisi de façon que les groupes à fonction de présentation puissent entrer en interaction avec une pluralité de sites cibles de liaison. La composition peut également comporter un vecteur pharmaceutiquement acceptable. Selon une autre réalisation, l'agent de présentation peut constituer lui-même son propre vecteur pharmaceutiquement acceptable. L'invention concerne également le traitement d'affections ou d'états. Ce traitement consiste en l'administration à un sujet d'une pluralité de groupes A de façon que le traitement se produise. Le traitement se produit du fait de l'interaction d'un agent de présentation polyvalent avec une pluralité de sites cibles de liaison B. Sous d'autres aspects, l'invention concerne, d'une part des agents de présentation polyvalents emballés avec un mode d'emploi destiné aux traitements considérés, et d'autre part des procédés de conception, d'agents de présentation polyvalent convenant particulièrement dans le cadre des procédés et traitements de l'invention. Les agents de présentation polyvalents de l'invention assurent une liaison spécifique, ce qui est relativement avantageux. En outre, ces agents de présentation polyvalents permettent des interactions positives et négatives.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4378197P | 1997-04-11 | 1997-04-11 | |
US60/043,781 | 1997-04-11 | ||
US4382697P | 1997-04-14 | 1997-04-14 | |
US60/043,826 | 1997-04-14 | ||
PCT/US1998/007171 WO1998046270A2 (fr) | 1997-04-11 | 1998-04-09 | Molecules presentant une pluralite de groupes fonctionnels actifs |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2286692A1 true CA2286692A1 (fr) | 1998-10-22 |
Family
ID=26720814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002286692A Abandoned CA2286692A1 (fr) | 1997-04-11 | 1998-04-09 | Molecules presentant une pluralite de groupes fonctionnels actifs |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0973551A2 (fr) |
JP (1) | JP2002503223A (fr) |
KR (1) | KR20010006280A (fr) |
CN (1) | CN1269013A (fr) |
AU (1) | AU743028B2 (fr) |
BR (1) | BR9808521A (fr) |
CA (1) | CA2286692A1 (fr) |
WO (1) | WO1998046270A2 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2330611A1 (fr) | 1998-05-22 | 1999-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Molecules bifonctionnelles et therapies basees sur celles-ci |
JP3468149B2 (ja) * | 1999-02-19 | 2003-11-17 | 松下電器産業株式会社 | 微細物体の操作装置および操作方法 |
EP1177029B1 (fr) * | 1999-05-10 | 2004-03-17 | Glaxo Group Limited | Station de travail haute capacite de criblage de formes cristallines et son utilisation |
US6887842B1 (en) | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
US7220552B1 (en) | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
WO2001035978A1 (fr) | 1999-11-19 | 2001-05-25 | The Board Of Trustees Of The Leland Stanford Junior University | Molecules bifonctionnelles ciblees et therapies basees sur celles-ci |
EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
KR100543171B1 (ko) * | 2002-05-31 | 2006-01-20 | 한국과학기술원 | 분자수준에서 배향성을 조절하면서 항체 단분자막을 제조하는 방법 |
CA2583666A1 (fr) * | 2004-10-13 | 2006-04-27 | Ilypsa, Inc. | Preparations pharmaceutiques comprenant un oligosaccharide complexant les toxines et une particule polymere |
CN101325963B (zh) | 2005-10-08 | 2016-01-27 | 博泰迪亚制药公司 | 用于眼部病症的补体抑制素和其类似物 |
ES2545775T3 (es) | 2007-02-05 | 2015-09-15 | Apellis Pharmaceuticals, Inc. | Análogos de compstatina para uso en el tratamiento de afecciones inflamatorias del sistema respiratorio |
EP2139524A1 (fr) * | 2007-03-23 | 2010-01-06 | The Governors of the University of Alberta | Polymères hétérobifonctionnels multivalents et leurs procédés d'utilisation |
EP2192923A2 (fr) * | 2007-08-27 | 2010-06-09 | Massachusetts Institute of Technology | Inhibiteurs du virus de la grippe couplés à un polymère bifonctionnel |
CN107050422B (zh) | 2011-05-11 | 2021-11-09 | 阿佩利斯制药公司 | 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途 |
MX363606B (es) | 2011-06-22 | 2019-03-28 | Apellis Pharmaceuticals Inc | Uso de inhibidores del complemento en trastornos crónicos. |
SI3660033T1 (sl) | 2012-11-15 | 2021-09-30 | Apellis Pharmaceuticals, Inc. | Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki |
WO2014134297A1 (fr) * | 2013-02-28 | 2014-09-04 | The University Of Southern Mississippi | Liaison covalente de bactériophages à des surfaces polymères |
RU2770099C2 (ru) | 2015-10-07 | 2022-04-14 | Апеллис Фармасьютикалс, Инк. | Схемы введения |
KR20210084552A (ko) | 2018-10-29 | 2021-07-07 | 위스콘신 얼럼나이 리서어치 화운데이션 | 향상된 암 면역요법을 위한 면역관문 억제제와 복합체화된 덴드리틱 폴리머 |
US11564995B2 (en) | 2018-10-29 | 2023-01-31 | Wisconsin Alumni Research Foundation | Peptide-nanoparticle conjugates |
KR20220092557A (ko) | 2019-10-29 | 2022-07-01 | 위스콘신 얼럼나이 리서어치 화운데이션 | 펩티드-나노입자 접합체 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE463314B (sv) * | 1989-03-01 | 1990-11-05 | Biocarb Ab | Sampolymerer av en n-acylerad glykosylamin och en amid, n-akryloyl-eller metakryloylglykosylaminer samt foerfarande foer framstaellning av dessa |
DE19640791A1 (de) * | 1996-10-02 | 1998-04-16 | Syntesome Ges Fuer Medizinisch | Glycokonjugate als Inhibitoren der viralen Zelladhäsion |
-
1998
- 1998-04-09 WO PCT/US1998/007171 patent/WO1998046270A2/fr not_active Application Discontinuation
- 1998-04-09 CA CA002286692A patent/CA2286692A1/fr not_active Abandoned
- 1998-04-09 JP JP54407498A patent/JP2002503223A/ja active Pending
- 1998-04-09 CN CN98804085A patent/CN1269013A/zh active Pending
- 1998-04-09 AU AU71069/98A patent/AU743028B2/en not_active Ceased
- 1998-04-09 EP EP98918079A patent/EP0973551A2/fr not_active Withdrawn
- 1998-04-09 KR KR1019997009364A patent/KR20010006280A/ko not_active Application Discontinuation
- 1998-04-09 BR BR9808521-2A patent/BR9808521A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2002503223A (ja) | 2002-01-29 |
CN1269013A (zh) | 2000-10-04 |
KR20010006280A (ko) | 2001-01-26 |
BR9808521A (pt) | 2000-05-23 |
AU743028B2 (en) | 2002-01-17 |
WO1998046270A3 (fr) | 1999-01-07 |
WO1998046270A2 (fr) | 1998-10-22 |
EP0973551A2 (fr) | 2000-01-26 |
AU7106998A (en) | 1998-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU743028B2 (en) | Molecules presenting a multitude of active moieties | |
Percec et al. | Modular synthesis of amphiphilic Janus glycodendrimers and their self-assembly into glycodendrimersomes and other complex architectures with bioactivity to biomedically relevant lectins | |
Roy | Syntheses and some applications of chemically defined multivalent glycoconjugates | |
Werz et al. | Carbohydrates as the next frontier in pharmaceutical research | |
Zanini et al. | Synthesis of new α-thiosialodendrimers and their binding properties to the sialic acid specific lectin from Limax flavus | |
Bovin et al. | Polymer-immobilized carbohydrate ligands: versatile chemical tools for biochemistry and medical sciences | |
Wu et al. | “Sweet” architecture-dependent uptake of glycocalyx-mimicking nanoparticles based on biodegradable aliphatic polyesters by macrophages | |
Kensinger et al. | Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120 | |
Gomez-Garcia et al. | Probing carbohydrate-lectin recognition in heterogeneous environments with monodisperse cyclodextrin-based glycoclusters | |
Thoma et al. | Nanomolar E-selectin inhibitors: 700-fold potentiation of affinity by multivalent ligand presentation | |
Matsushita et al. | Artificial Golgi apparatus: globular protein-like dendrimer facilitates fully automated enzymatic glycan synthesis | |
Gao et al. | Exploring and controlling the polymorphism in supramolecular assemblies of carbohydrates and proteins | |
Hartweg et al. | Synthetic glycomacromolecules of defined valency, absolute configuration, and topology distinguish between human lectins | |
JPH09509979A (ja) | ポリマー抱合マロン酸誘導体並びに薬剤および診断剤としてのそれらの使用 | |
Prakobphol et al. | Separate oligosaccharide determinants mediate interactions of the low-molecular-weight salivary mucin with neutrophils and bacteria | |
WO1998047002A2 (fr) | Bibliotheques combinatoires de presentation polyvalente et leurs utilisations | |
AU5145099A (en) | Treatment of bacterial infections | |
Bruehl et al. | Polymerized liposome assemblies: bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands | |
Eissa et al. | Glycopolymer conjugates | |
Li et al. | Synthesis and assessment of globotriose–chitosan conjugate, a novel inhibitor of Shiga toxins produced by Escherichia coli | |
Hoyos et al. | Synthesis of glycodendrimers with antiviral and antibacterial activity | |
Leyden et al. | Synthesis of bivalent lactosides based on terephthalamide, N, N′-diglucosylterephthalamide, and glycophane scaffolds and assessment of their inhibitory capacity on medically relevant lectins | |
Nagao et al. | Synthesis of various glycopolymers bearing sialyllactose and the effect of their molecular mobility on interaction with the influenza virus | |
Neuhaus et al. | Asymmetrically branched precision glycooligomers targeting langerin | |
Bi et al. | Dynamic glycopeptide dendrimers: Synthesis and their controllable self-assembly into varied glyco-nanostructures for the biomimicry of glycans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |